Free Trial
NASDAQ:RAPP

Rapport Therapeutics (RAPP) Stock Price, News & Analysis

Rapport Therapeutics logo
$18.07 +0.21 (+1.18%)
(As of 12/20/2024 05:16 PM ET)

About Rapport Therapeutics Stock (NASDAQ:RAPP)

Key Stats

Today's Range
$17.52
$19.08
50-Day Range
$17.86
$29.23
52-Week Range
$16.55
$29.74
Volume
527,558 shs
Average Volume
155,880 shs
Market Capitalization
$660.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00
Consensus Rating
Buy

Company Overview

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Rapport Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
31st Percentile Overall Score

RAPP MarketRank™: 

Rapport Therapeutics scored higher than 31% of companies evaluated by MarketBeat, and ranked 795th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rapport Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Rapport Therapeutics has received no research coverage in the past 90 days.

  • Read more about Rapport Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Rapport Therapeutics are expected to grow in the coming year, from ($3.65) to ($3.37) per share.

  • Percentage of Shares Shorted

    10.25% of the float of Rapport Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Rapport Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Rapport Therapeutics has recently increased by 2.87%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Rapport Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Rapport Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.25% of the float of Rapport Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Rapport Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Rapport Therapeutics has recently increased by 2.87%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Rapport Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Rapport Therapeutics this week, compared to 2 articles on an average week.
Receive RAPP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RAPP Stock News Headlines

WARNING: “Buffett Indicator” flashing for first time in 50 years
Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
Rapport semestriel Pilier 3 - 30 juin 2024
See More Headlines

RAPP Stock Analysis - Frequently Asked Questions

Rapport Therapeutics' stock was trading at $25.01 at the beginning of 2024. Since then, RAPP stock has decreased by 27.7% and is now trading at $18.07.
View the best growth stocks for 2024 here
.

Rapport Therapeutics (NASDAQ:RAPP) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by $1.02.

Rapport Therapeutics (RAPP) raised $136 million in an initial public offering (IPO) on Friday, June 7th 2024. The company issued 8,000,000 shares at a price of $17.00 per share.

Rapport Therapeutics' lock-up period expired on Wednesday, December 4th. Rapport Therapeutics had issued 8,000,000 shares in its public offering on June 7th. The total size of the offering was $136,000,000 based on an initial share price of $17.00. Since the end of Rapport Therapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Rapport Therapeutics' top institutional shareholders include FMR LLC (15.00%), Geode Capital Management LLC (0.55%), Eventide Asset Management LLC (0.30%) and The Manufacturers Life Insurance Company (0.21%).
View institutional ownership trends
.

Shares of RAPP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rapport Therapeutics investors own include Alpha Metallurgical Resources (AMR), Arch Resources (ARCH), Global X Copper Miners ETF (COPX), Hims & Hers Health (HIMS), Karuna Therapeutics (KRTX), Longboard Pharmaceuticals (LBPH) and Navios Maritime Partners (NMM).

Company Calendar

Last Earnings
8/08/2024
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RAPP
Previous Symbol
NASDAQ:RAPP
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.00
High Stock Price Target
$35.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+93.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$660.93 million
Optionable
N/A
Beta
N/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:RAPP) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners